Primo-indication
Imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.Imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
Intervention Type
Pharmaceutical
Solid/Hematological
Hematological
Cancer Type
Multiple myeloma
Therapy Types
Immunomodulatory Agent
Regulatory
FDA
Regulatory Pathway: n/a
EMA
Regulatory Pathway: standard approval
Availability in other countries
N/A
Focus Area
Cancer
ASMR
III
Medical Need
Unmet
SMR
IMPORTANT
Orphan Status
No